Wedoany.com Report on Feb 4th, it was reported that OpenAI CEO Sam Altman revealed that the company is planning to assist pharmaceutical companies in using AI technology to accelerate the drug research and development process for new drugs or therapies through multiple modes and seeking to generate profits from it. Sam Altman stated, "We hope to lower the barrier for pharmaceutical companies to apply AI technology through flexible cooperation methods while promoting the faster implementation of medical innovation achievements."

According to reports, OpenAI is considering investing in or providing subsidies to pharmaceutical companies participating in drug R&D and obtaining returns through charging patent licensing fees or technology usage fees. In addition, the company has also proposed sharing the cost of using AI models with pharmaceutical companies and proportionally sharing the final R&D achievements. This model combines OpenAI's technological advantages with the drug R&D experience of pharmaceutical companies, aiming to shorten the new drug development cycle and reduce the risk of failure. However, Sam Altman emphasized that no specific cooperation agreements have been reached with any pharmaceutical companies yet, and the relevant models are still in the exploration stage.

It is worth noting that in January of this year, OpenAI launched the OpenAI for Healthcare product portfolio for the medical industry and deployed the ChatGPT Healthcare version in multiple medical institutions. This product assists medical staff in completing tasks such as medical record organization and generating diagnostic and treatment suggestions by optimizing natural language processing capabilities, thereby improving medical efficiency. This announcement of assisting pharmaceutical companies in drug R&D further reflects OpenAI's deepening layout in the medical field.